Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Neuropathic Pruritus, Formication, Iron Deficiency, Dopamine: Piecing the Puzzle Together

Description

The presentation examines the intricacies of neuropathic pruritus, a unique type of itch distinct from common dermatological conditions, focusing on its connection to formication—a crawling sensation on the skin. The speaker discusses iron deficiency and dopamine's role in these sensations, positing that neuropathic pruritus is influenced by neuropeptides and different inflammatory mechanisms than those typically seen in conditions like psoriasis and eczema. Formication, often exacerbated by stress and related to psychiatric conditions, can be influenced by medications that affect the dopamine system. The talk outlines the risk factors, potential treatments, and the neurobiological underpinnings of the condition, including the role of cytokines like oncostatin M and iron metabolism. Emerging therapies that target specific pathways are highlighted, suggesting a multifactorial approach to treatment, including the management of iron deficiency and the role of antipsychotics as a potential innovative treatment avenue. Ultimately, the speaker emphasizes the need for a better understanding of the interactions between iron levels, dopamine, and inflammatory processes in managing neuropathic itch and formication.

View more

Conclusions

  • Neuropathic pruritus presents with itch that may not correlate with visible rashes or may involve disproportionate symptoms.
  • Formication, characterized by a crawling sensation without external stimuli, is linked to dopamine dysregulation and has associations with anxiety and iron deficiency.
  • Iron deficiency appears to be prevalent in a significant portion of patients with formication, potentially influencing dopamine metabolism.
  • Patients with formication often show elevated levels of oncostatin M, suggesting a role in itch amplification and severity.
  • Antipsychotic medications may provide not only dopamine blockade but also anti-inflammatory effects through JAK/STAT inhibition, potentially benefiting patients with formication.
  • New therapies targeting neuropeptides and associated pathways show promise in treating pruritus-related conditions, emphasizing a shift in therapeutic focus from traditional antipruritic strategies.
  • Am J Psychiatry. 2023 Feb 22;appiajp20220737. doi: 10.1176/appi.ajp.20220737. Online ahead of print. Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder Jon E Grant et al.
  • J Am Acad Dermatol. 2023 Apr 12;S0190-9622(23)00586-8. doi: 10.1016/j.jaad.2023.03.051. A Phase 2 Study of Oral Difelikefalin in Subjects With Chronic Kidney Disease and Moderate-to-Severe Pruritus Gil Yosipovitch et al.
  • Exp Dermatol. 2021 Jun:30(6):804-810. doi: 10.1111/exd.14279. Epub 2021 Feb 1. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta Takashi Hashimoto et al.
  • Lancet. 1979 Mar 17;1(8116):605. doi: 10.1016/s0140-6736(79)91025-0. Treatment of metastatic malignant melanoma with pimozide R N Taub, M A Baker
  • Blood. 2011 Mar 24;117(12):3421-9. doi: 10.1182/blood-2009-11-255232. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
  • Genes Cancer. 2012 Jul;3(7-8):503-11. doi: 10.1177/1947601912466555. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
  • Int J Oncol. 2016 Jan;48(1):322-8. doi: 10.3892/ijo.2015.3229. Epub 2015 Nov 4. The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation.
  • Subbanna M, Shivakumar V, Venugopal D, Narayanaswamy JC, Berk M, Varambally S, Venkatasubramanian G, Debnath M. Impact of antipsychotic medication on IL-6/STAT3 signaling axis in peripheral blood mononuclear cells of drug-naive schizophrenia patients. Psychiatry Clin Neurosci. 2020 Jan;74(1):64-69. doi: 10.1111/pcn.12938. Epub 2019 Nov 2.